Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
21.21
+0.39 (1.87%)
Nov 20, 2024, 4:00 PM EST - Market closed

KNSA Revenue

Kiniksa Pharmaceuticals International, had revenue of $112.21M in the quarter ending September 30, 2024, with 67.37% growth. This brings the company's revenue in the last twelve months to $384.10M, up 54.41% year-over-year. In the year 2023, Kiniksa Pharmaceuticals International, had annual revenue of $270.26M with 22.74% growth.

Revenue (ttm)
$384.10M
Revenue Growth
+54.41%
P/S Ratio
3.92
Revenue / Employee
$1,293,259
Employees
297
Market Cap
1.53B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023270.26M50.08M22.74%
Dec 31, 2022220.18M181.64M471.24%
Dec 31, 202138.54M--
Dec 31, 2020---
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Teladoc Health 2.59B
10x Genomics 629.74M
InMode 423.75M
Immunocore Holdings 296.31M
Dynavax Technologies 260.81M
Travere Therapeutics 203.45M
Arvinas 161.10M
Nurix Therapeutics 56.42M
Revenue Rankings